Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 25,096,153 shares of its common stock at a price to the public of US$2.60 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 3,750,000 shares of common stock at a purchase price of US$2.599 per share, which equals the public offering price per share of the common stock less the US$0.001 exercise price per share of each pre-funded warrant. The offering is expected to close on November 14, 2025, subject to the satisfaction of customary closing conditions.
Latham & Watkins LLP represents the underwriters in the offering, with a Capital Markets team led by New York partner Nathan Ajiashvili, with associates Sandy Kugbei and Jie Lin Nai, with assistance from Abdullah Khan.
